TetraLogic Pharma (TLOG) Misses Q4 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Tetralogic Pharmaceuticals (TLOG) Target Cut at Needham & Company; 'Buy' Maintained
March 2, 2015 8:39 AM ESTNeedham & Company analyst Chad Messer cut his price target on Tetralogic Pharmaceuticals (NASDAQ: TLOG) to $10.00 (from $16.00) while maintaining a Buy rating following Q4 results and an update on its clinical programs.
Messer commented, "Birinapant is in 3 ongoing studies that will all... More
